In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Teva boosts US/key European generics with $9bn Barr purchase

Executive Summary

Israeli generics powerhouse Teva is negotiating its third and most expensive acquisition this year with a proposed $8.7bn takeover ($4.3bn in cash/$2.9bn in stock, plus the assumption of $1.5bn in debt) of Barr Pharmaceuticals, the world's fourth-largest generics firm.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies